Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Unity Biotech (UBX)
:UBX
RESEARCH TOOLSreports
Holding UBX?
Track your performance easily
UBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $2.02
Previous CloseN/A
Volume348.46K
Average Volume (3M)234.49K
Market Cap
$28.48M
Enterprise Value$20.16M
Total Cash (Recent Filing)$89.29M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Mar 12, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding16,850,350
10 Day Avg. Volume477,640
30 Day Avg. Volume234,493
Standard Deviation0.23
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.10
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue5.03
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$6.00Price Target Upside255.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Unity Biotechnology News
PremiumCompany Announcements
Unity Biotechnology Focuses on Promising DME Treatment
Ownership Overview
10.00% Insiders
4.45% Mutual Funds
13.40% Other Institutional Investors
68.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UBX FAQ
What was Unity Biotech’s price range in the past 12 months?
Unity Biotech lowest stock price was $0.94 and its highest was $2.02 in the past 12 months.
What is Unity Biotech’s market cap?
Unity Biotech’s market cap is $28.48M.
When is Unity Biotech’s upcoming earnings report date?
Unity Biotech’s upcoming earnings report date is Mar 12, 2025 which is in 53 days.
How were Unity Biotech’s earnings last quarter?
Unity Biotech released its earnings results on Nov 04, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.404 by $0.024.
Is Unity Biotech overvalued?
According to Wall Street analysts Unity Biotech’s price is currently Undervalued.
Does Unity Biotech pay dividends?
Unity Biotech does not currently pay dividends.
What is Unity Biotech’s EPS estimate?
Unity Biotech’s EPS estimate is -0.39.
How many shares outstanding does Unity Biotech have?
Unity Biotech has 16,850,350 shares outstanding.
What happened to Unity Biotech’s price movement after its last earnings report?
Unity Biotech reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.404. Following the earnings report the stock price went down -3.968%.
Which hedge fund is a major shareholder of Unity Biotech?
Currently, no hedge funds are holding shares in UBX
---
Unity Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (255.03% Upside)
$6.00 (255.03% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.70%
12-Months-Change
Fundamentals
Return on Equity
-86.95%
Trailing 12-Months
Asset Growth
-31.96%
Trailing 12-Months
Company Description
Unity Biotech
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
---
UBX Stock 12 Month Forecast
Average Price Target
$6.00
▲(255.03% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Bioxcel Therapeutics
―
Cellectar Biosciences
―
Fate Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering UBX
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-15.77%
reiterated a buy rating 5 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -15.77% per trade.
---